Patents by Inventor Markus Beier

Markus Beier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200199672
    Abstract: The present invention relates to a method of removing an RNA fraction with ?200 nucleotides in length from a whole blood sample. The present invention also relates to a method of purifying an RNA fraction with <200 nucleotides in length from a whole blood sample. The present invention further relates to a method of determining the level of RNA molecules with <200 nucleotides in length. In addition, the present invention relates to a method for diagnosing a disease in an individual. Moreover, the present invention relates to a kit which is useful for carrying out the methods of the present invention.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 25, 2020
    Inventors: Thomas LAUFER, Markus BEIER, Mustafa KAHRAMAN, Andreas KELLER
  • Publication number: 20200060987
    Abstract: A pharmaceutical composition comprising a semifluorinated alkane of formula (I): F(CF2)n(CH2)mH, wherein n is an integer from 4 to 6, and m is an integer from 5 to 8, for use in the treatment or prevention of a disease or condition relating to an ocular surface of an eye of an individual, wherein the individual is a contact lens wearer, and wherein the contact lens is a hydro gel contact lens and the composition is administered topically to a surface of the eye of the individual before the contact lens is inserted to the eye of the individual and/or during contact lens wear and/or after the contact lens has been removed from the eye of the individual, or wherein the contact lens is a silicone hydrogel contact lens and the composition is administered topically to a surface of the eye of the individual after the contact lens has been removed from the eye of the individual.
    Type: Application
    Filed: May 9, 2018
    Publication date: February 27, 2020
    Inventors: Bernhard GÜNTHER, Markus BEIER, Oliver SCHLÜTER
  • Publication number: 20200024667
    Abstract: The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient.
    Type: Application
    Filed: August 16, 2019
    Publication date: January 23, 2020
    Inventors: Andreas Keller, Markus Beier, Matthias Scheffler, Anke Wendschlag, Orhan Aktas, Jens Ingwersen, Hans-Peter Hartung, Patrick Kury, Timour Prozorovski
  • Patent number: 10428382
    Abstract: The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: October 1, 2019
    Assignee: Hummingbird Diagnostics GmbH
    Inventors: Andreas Keller, Markus Beier, Matthias Scheffler, Anke Wendschlag, Orhan Aktas, Jens Ingwersen, Hans-Peter Hartung, Patrick Küry, Timour Prozorovski
  • Publication number: 20180360908
    Abstract: The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventors: Markus BEIER, Jörg HAISSER, Alice MEIDES, Sonja KRÖSSER, Hartmut VOSS, Frank LÖSCHER, Bernhard GÜNTHER
  • Patent number: 10000810
    Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 19, 2018
    Assignee: Hummingbird Diagnostics GmbH
    Inventors: Andreas Keller, Eckart Meese, Anne Borries, Peer Friedrich Staehler, Markus Beier
  • Publication number: 20180087111
    Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.
    Type: Application
    Filed: August 8, 2017
    Publication date: March 29, 2018
    Inventors: Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
  • Publication number: 20180037956
    Abstract: The present invention relates to a method for diagnosis of a change of the status of health of a subject based on the determination of expression profiles of miRNAs.
    Type: Application
    Filed: February 24, 2016
    Publication date: February 8, 2018
    Inventors: Markus Beier, Thomas Brefort, Jochen Kohlhaas, Andreas Keller
  • Patent number: 9822416
    Abstract: The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: November 21, 2017
    Assignee: Hummingbird Diagnostics GmbH
    Inventors: Andreas Keller, Matthias Scheffler, Markus Beier
  • Patent number: 9790554
    Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: October 17, 2017
    Assignee: Hummingbird Diagnostics GmbH
    Inventors: Andreas Keller, Markus Beier, Eckart Meese, Petra Leidinger, Anke Wendschlag
  • Publication number: 20170267999
    Abstract: The invention relates to methods and devices for preparing synthetic nucleic acids.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 21, 2017
    Inventors: Peer F. STAEHLER, Raphael CARAPITO, Cord F. STAEHLER, Mark MATZAS, Jack T. LEONARD, Joachim JAEGER, Markus BEIER
  • Patent number: 9758827
    Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: September 12, 2017
    Assignee: Comprehensive Biomarker Center GmbH
    Inventors: Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
  • Patent number: 9745630
    Abstract: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing prostate cancer based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: August 29, 2017
    Assignee: Hummingbird Diagnostics GmbH
    Inventors: Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
  • Patent number: 9702008
    Abstract: The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: July 11, 2017
    Assignee: HUMMINGBIRD DIAGNOSTICS GMBH
    Inventors: Andreas Keller, Eckart Meese, Anne Borries, Peer Friedrich Staehler, Markus Beier
  • Publication number: 20170175192
    Abstract: The present invention relates to methods, kits and uses for diagnosing heart failure using miRNA-biomarker from blood.
    Type: Application
    Filed: May 20, 2015
    Publication date: June 22, 2017
    Applicant: HUMMINGBIRD DIAGNOSTICS GMBH
    Inventors: Markus BEIER, Thomas BREFORT
  • Patent number: 9631241
    Abstract: Described herein are non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer a body fluid sample from a subject. Further described herein are sets of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. In addition, described herein are sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 25, 2017
    Assignee: Comprehensive Biomarker Center GmbH
    Inventors: Andreas Keller, Markus Beier, Eckart Meese, Petra Leidinger, Anke Wendschlag
  • Patent number: 9611511
    Abstract: The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of an acute coronary syndrome in a blood sample from a human. Further, the present invention relates to means for diagnosing and/or prognosing of an acute coronary syndrome comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of an acute coronary syndrome based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome compared to a reference. In addition, the present invention relates to a kit for diagnosing and/or prognosing of an acute coronary syndrome comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome and at least one reference.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 4, 2017
    Assignee: COMPREHENSIVE BIOMARKER CENTER GMBH
    Inventors: Andreas Keller, Peer F. Stähler, Markus Beier, Benjamin Meder, Hugo A. Katus, Wolfgang Rottbauer
  • Publication number: 20170002411
    Abstract: The present invention relates to methods, kits and uses for determining platelet-miRNAs in a from a platelet-comprising fraction derived from a whole blood sample from a subject affected or suspected to be affected by Alzheimer's Disease.
    Type: Application
    Filed: December 19, 2014
    Publication date: January 5, 2017
    Applicant: Hummingbird Diagnostics GmbH
    Inventor: Markus Beier
  • Patent number: 9528158
    Abstract: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 27, 2016
    Assignee: Comprehensive Biomarker Center GmbH
    Inventors: Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
  • Publication number: 20160326588
    Abstract: The present invention relates to methods, kits and means for diagnosing Parkinson's disease in a blood sample from a subject. Further, the present invention relates to a set of polynucleotides for detecting sets of miRNAs for diagnosing Parkinson's disease in a blood sample from a subject.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 10, 2016
    Applicant: Hummingbird Diagnostics GmbH
    Inventor: Markus Beier